Research programme: protein therapies - CureVacAlternative Names: Protein replacement therapy - CureVac; RNAntibody®; RNArt®protein therapy; Sequence engineered mRNA - CureVac
Latest Information Update: 11 Nov 2016
At a glance
- Originator CureVac
- Developer Acuitas Therapeutics; CureVac
- Class Proteins
- Mechanism of Action Protein replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Rabies; Unspecified